

<b>DATE:</b>	13 May 2024
<b>TO:</b>	All Zones: All Healthcare Professionals and Providers
<b>FROM:</b>	Clinical Biochemistry, South Sector, Alberta Precision Laboratories (APL)
<b>RE:</b>	<b>Test Change and Updated Interpretive Comment for C-telopeptide Assay</b>

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective May 21, 2024, the provincial testing platform for serum C-telopeptide (CTX) will be updated to accommodate the retirement of an older analyzer.
- Significant bias exists across the reportable range between CTX performed on the new and old instrumentation (see table below).

<b>Expected bias with new assay</b>	
<b>CTX Range</b>	<b>Average Bias</b>
Entire measuring range (10–3000 ng/L)	10%
<200 ng/L	-6%
200–500 ng/L	10%
>500 ng/L	20%

- To aid in appropriate result interpretation, the reference interval will be replaced with an interpretive comment.

### Background

- CTX is useful for evaluating anti-bone resorption therapy and should not be used for diagnosing bone disease. Therefore, a reference interval will no longer be applied to CTX results. Instead, an interpretive comment will help with result interpretation.

### How this will impact you

- Please be aware of the potential bias between new and previous CTX results.

### Action Required

- Re-baseline patients using the new CTX assay if clinically indicated.

### Questions or Concerns may be directed to

- Dr. Michael Reid, Clinical Biochemist, APL-Calgary, [Michael.Reid@aplabs.ca](mailto:Michael.Reid@aplabs.ca)

### Reviewed and Approved by

- Dr. Jessica Gifford, Lead, Chemistry, Hub Lab, South Sector, APL
- Dr. Paul Klonowski Associate Medical Director, Hub Lab, South Sector APL

*Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.*